<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
<title>Pulmonologie</title>
<link href="http://repository.usmf.md:80/xmlui/handle/20.500.12710/378" rel="alternate"/>
<subtitle/>
<id>http://repository.usmf.md:80/xmlui/handle/20.500.12710/378</id>
<updated>2026-05-19T16:47:46Z</updated>
<dc:date>2026-05-19T16:47:46Z</dc:date>
<entry>
<title>Influenţa eficacităţii trimetazidinei în tratamentul complex al bronhopneumopatiei cronice obstructive asociate cu cardiopatia ischemică</title>
<link href="http://repository.usmf.md:80/xmlui/handle/20.500.12710/4895" rel="alternate"/>
<author>
<name>Condaruc, Natalia</name>
</author>
<author>
<name>Butorov, Valentina</name>
</author>
<id>http://repository.usmf.md:80/xmlui/handle/20.500.12710/4895</id>
<updated>2019-06-25T21:51:56Z</updated>
<published>2012-01-01T00:00:00Z</published>
<summary type="text">Influenţa eficacităţii trimetazidinei în tratamentul complex al bronhopneumopatiei cronice obstructive asociate cu cardiopatia ischemică
Condaruc, Natalia; Butorov, Valentina
COPD associated with ischemic coronary disease is not only a medical problem, but also a&#13;
socio-economic one, which tends to affect younger people, physically active. Treatment of&#13;
associated pathology still remains a current direction in contemporary medicine.&#13;
The study included 52 patients with II degree of COPD, associated with ischemic coronary&#13;
disease. The patients were investigated by ECG, Hollter, echocardiography and spirography.&#13;
Combined treatment with trimetazidine was established to be more efficient versus the&#13;
comparison group.&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
BPCO asociată cu CI reprezintă nu doar o problemă medicală, dar şi social-economică&#13;
importantă, care tinde să afecteze populaţia tot mai tânără, aptă de muncă, tratamentul patologiei&#13;
asociate rămânând o direcţie actuală în medicina contemporană.&#13;
Studiul a inclus 52 pacienti cu BPCO gr.II asociată cu CI cărora li s-a evaluat ECG, ECGHollter,&#13;
ecocardiografia şi spirografia. S-a stabilit eficacitatea mai pronunţată a tratamentului&#13;
combinat cu trimetazidină prin ameliorarea indicilor clinici la pacienţii din lotul respectiv versus&#13;
celui de comparaţie.
Catedra Medicina Internă Nr.3, USMF „N. Testemiţanu”
</summary>
<dc:date>2012-01-01T00:00:00Z</dc:date>
</entry>
<entry>
<title>Tromboembolismul pulmonar la pacienţii cu factori de risc</title>
<link href="http://repository.usmf.md:80/xmlui/handle/20.500.12710/4897" rel="alternate"/>
<author>
<name>Muravca, Alexei</name>
</author>
<author>
<name>Anghel, Tatiana</name>
</author>
<id>http://repository.usmf.md:80/xmlui/handle/20.500.12710/4897</id>
<updated>2019-06-25T21:51:56Z</updated>
<published>2012-01-01T00:00:00Z</published>
<summary type="text">Tromboembolismul pulmonar la pacienţii cu factori de risc
Muravca, Alexei; Anghel, Tatiana
Pulmonary thromboembolism is a multifactorial disease, influenced by the interaction of&#13;
genetic and acquired risk factors. Almost 80-90% of cases of DVT detailed research may reveal&#13;
at least one risk factor. Risk factors interact with one another, acting synergistically and&#13;
additively. Acquired “classic” risk factors– age, obesity; “risk periods” like surgery, trauma,&#13;
immobilization, medical conditions, pregnancy, postpartum period, oral contraceptive use, not&#13;
only predispose apparently healthy people to DTV, but trigger DTV on genetically prone land.&#13;
&#13;
&#13;
&#13;
Tromboembolismul pulmonar (TEAP) reprezintă o afecţiune multifactorială, fiind&#13;
influenţat de interacţiunea unor factori de risc genetici şi dobândiţi. Aproape 80-90% din cazurile&#13;
de TVP la o cercetare amănunţită poate evidenţia cel puţin un factor de risc. Factorii de risc&#13;
interacţionează între ei, acţionând sinergic şi aditiv. Factorii „clasici” dobândiţi de risc - vârsta,&#13;
obezitatea; “perioadele de risc” reprezentate de intervenţii chirurgicale, traumatisme,&#13;
imobilizare, afecţiuni medicale, sarcină, perioada postpartum, utilizarea contraceptivelor orale, &#13;
nu numai predispun persoane aparent sănătoase la TVP, dar reprezintă trigger pentru TVP pe un&#13;
teren predispus genetic
(Conducător ştiinţific – Brocovschi Victoria, asistent universitar)&#13;
Clinica medicală N 2, USMF „Nicolae Testemiţanu”
</summary>
<dc:date>2012-01-01T00:00:00Z</dc:date>
</entry>
<entry>
<title>Tromboza venoasă profundă la pacientul trombofilic – risc crescut pentru tromboembolism pulmonar.</title>
<link href="http://repository.usmf.md:80/xmlui/handle/20.500.12710/4896" rel="alternate"/>
<author>
<name>Muravca, Alexei</name>
</author>
<author>
<name>Anghel, Tatiana</name>
</author>
<id>http://repository.usmf.md:80/xmlui/handle/20.500.12710/4896</id>
<updated>2019-06-25T21:51:56Z</updated>
<published>2012-01-01T00:00:00Z</published>
<summary type="text">Tromboza venoasă profundă la pacientul trombofilic – risc crescut pentru tromboembolism pulmonar.
Muravca, Alexei; Anghel, Tatiana
Thrombophilia – characterized a series of hypercoagulable states that predispose to the&#13;
formation of intravascular thrombosis. This syndrome is usually rare, but the importance of&#13;
knowing it can not be underestimated because thrombophilia is the main risk genetically&#13;
acquired which predisposes people to develop advance venous thrombophilia and leads to a high&#13;
incidence of pulmonary thromboembolism which has an increased mortality.&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
Trombofilia caracterizează o serie de stări de hipercoagulabilitate, care predispun la&#13;
formarea de tromboze intravasculare. Acest sindrom de regulă se întâlneşte rar, însă importanţa&#13;
cunoaşterii nu poate fi subestimată deoarece se ştie că este principalul factor de risc dobândit &#13;
care predispune persoanele la formarea trombozei venoase profunde şi mai mult, la o incidenţă&#13;
crescută a tromboembolismului pulmonar.
Conducător ştiinţific – Brocovschi Victoria, asistent universitar&#13;
Clinica medicală N 2, USMF „Nicolae Testemiţanu”
</summary>
<dc:date>2012-01-01T00:00:00Z</dc:date>
</entry>
<entry>
<title>Aspectele clinico-farmacologice ale perindoprilului în tratamentul cordului pulmonar cronic</title>
<link href="http://repository.usmf.md:80/xmlui/handle/20.500.12710/4894" rel="alternate"/>
<author>
<name>Butorov, Serghei</name>
</author>
<author>
<name>Gonciar, Veaceslav</name>
</author>
<author>
<name>Condaruc, Natalia</name>
</author>
<id>http://repository.usmf.md:80/xmlui/handle/20.500.12710/4894</id>
<updated>2019-06-25T21:51:56Z</updated>
<published>2012-01-01T00:00:00Z</published>
<summary type="text">Aspectele clinico-farmacologice ale perindoprilului în tratamentul cordului pulmonar cronic
Butorov, Serghei; Gonciar, Veaceslav; Condaruc, Natalia
The study included 46 patients with COPD complicated with CPH, treated with ACE&#13;
inhibitor - perindopril associated with basic therapy. It was found that the inclusion of&#13;
perindopril in the complex treatment of patients with COPD complicated by CPH improves the&#13;
clinical course of disease, beneficially acting on indices of central and intracardiac&#13;
hemodynamics and on cardiac arrhythmias.&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
&#13;
Studiul a inclus 46 pacienţi cu BPCO complicată cu CPC, cărora li s-a efectuat tratamentul&#13;
cu inhibitorul ECA – perindopril asociat cu terapia de bază. S-a constatat că includerea&#13;
perindoprilului în tratamentul complex al pacienţilor cu BPCO complicat cu CPC ameliorează&#13;
evoluţia clinică a maladiei, acţionează benefic asupra indicilor hemodinamicii centrale şi&#13;
intracardiace, şi asupra tulburărilor de ritm cardiac.
Catedra Farmacologie şi Farmacie Clinică, USMF „N. Testemiţanu”&#13;
Catedra Medicina Internă
</summary>
<dc:date>2012-01-01T00:00:00Z</dc:date>
</entry>
</feed>
